A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease

Chronic Kidney Disease Clinical Trial

Official title:

A Randomized, Double-Blind, Dose-escalating, Placebo Controlled, Phase I Study to Evaluate the Safety and Pharmacokinetics and Pharmacodynamics of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03976115
• Other study ID #: DDO-3055-101
• Status: Completed
• Phase: Phase 1
• Start date: July 18, 2019
• Est. completion date: May 11, 2021

Study information

• Verified date: June 2022
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with chronic kidney disease.

48 healthy volunteers will be enrolled in Part A, and 18 patients with chronic kidney disease will be enrolled in Part B.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: May 11, 2021
• Est. primary completion date: May 11, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers:

Male or female volunteers aged 18 to 45 years of age inclusive ; Hemoglobin is 120 to 160 g/L; In good health, at the discretion of the investigator, as determined by: medical history, physical examination, vital sign assessment, 12-lead ECG, clinical laboratory evaluations.

• Patients with chronic kidney disease : Male or female patients with chronic kidney disease who are 18 to 45 years of age inclusive; Hemoglobin is =100 g/L; 30mL/min/1.73m2 = eGFR = 60mL/min/1.73m2(according to CKD-EPI formula);

• Body weight is = 50kg, and 19kg/m2 = body mass index<26kg/m2 .

• Normal iron reserves (serum iron >61 g/dL and serum ferritin normal >30ng/mL).

• Signed informed consent.

Exclusion Criteria:

Healthy volunteers:

• The serum creatinine exceeded the upper limit of normal value in the screening period.

Healthy volunteers and patients with chronic kidney disease:

• Allergic to the study drug or any of its ingredients.

• Treating or treated with erythropoiesis stimulating agents for 1 month before screening.

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) or total bilirubin above 1.5 times normal upper limit (ULN) in the screening period.

• Have a history of blood donation or blood transfusion within 3 months.

• Vein blood collection is difficult or physical condition can not afford blood collection.

• Hepatitis b surface antigen (HBsAg), hepatitis c antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody test is positive in the screening period.

• Smoking 5 cigarettes per day on average within 3 months; or the average daily intake of alcohol within one week is more than 15g (15g alcohol is equivalent to 450mL beer or 150mL wine or 50mL low-alcohol liquor) or 2 days before taking the study drug and during the study period, tobacco, alcohol and caffeinated food or beverage are not prohibited, or those with special dietary requirements cannot comply with the unified diet.

• Those who have participated in clinical trials of any drug or medical device within 3 months prior to screening, or those who have participated in the drug trial within 5 half-lives prior to screening; any health product (within 1 week prior to administration), over-the-counter drug (2 weeks prior to administration) or prescription drug (1 month prior to administration) that affects the absorption, distribution, metabolism or excretion of the tested drug.

• With a history of drug abuse or positive screening/baseline test for substance abuse and drug urinalysis.

• During the study period and within 30 days after administration, men who are unwilling to take contraceptive measures and promise not to donate sperm are not allowed to participate in the study. Childbearing women who did not use contraception at least 14 days before administration; men and women who did not agree to use physical contraception during the study period.

• Women with serum HCG = 5 mIU/mL or nursing in the screening period or baseline

• Any physical or mental illness or condition that may increase the risk of the study, affect the subject's compliance with the protocol, or affect the subject's ability to complete the study, as determined by the study physician.

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• DDO-3055
Oral
• Placebos
Oral

Locations

Country	Name	City	State
China	Guangdong Provincial People's Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events(AEs) and Serious Adverse Events (SAEs)	Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events	from informed consent form signature to the end of the study (up to 14 days)
Secondary	Area under the plasma concentration versus time curve (AUC) of DDO-3055		Pre-dose to 72 hours after dose administration
Secondary	Maximum observed serum concentration (Cmax) of DDO-3055		Pre-dose to 72 hours after dose administration
Secondary	Time to maximum observed serum concentration (tmax) of DDO-3055		Pre-dose to 72 hours after dose administration
Secondary	Time to elimination half-life (t1/2) of DDO-3055		Pre-dose to 72 hours after dose administration
Secondary	Apparent total clearance of the drug from plasma after oral administration (CL/F) of DDO-3055		Pre-dose to 72 hours after dose administration
Secondary	Apparent volume of distribution after non-intravenous administration (V/F) of DDO-3055		Pre-dose to 72 hours after dose administration
Secondary	Renal clearance of the drug from plasma (CLR) of DDO-3055		Pre-dose to 72 hours after dose administration
Secondary	Changes in red blood cell count relative to baseline		up to 14 days
Secondary	Changes in reticulocyte count relative to baseline		up to 14 days
Secondary	Changes in hemoglobin relative to baseline		up to 14 days
Secondary	Changes in endogenous erythropoietin relative to baseline		up to 14 days